Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its ongoing imaging study for multiple sclerosis (MS), with patient enrollment hitting the halfway mark and preliminary data showing encouraging signals. The study, conducted in collaboration with Massachusetts General Hospital, is evaluating a novel positron emission tomography (PET) imaging tracer that could differentiate between reversible and permanent nerve damage in MS lesions.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide, with approximately 2.9 million people living with the condition globally, including nearly one million in the United States. Most diagnoses occur between the ages of 20 and 40, impacting patients during their most productive years. The ability to accurately assess nerve damage is critical for treatment decisions and drug development.
The imaging tracer under investigation aims to provide a non-invasive method to track disease progression and response to therapy. Early data from the study has shown a meaningful signal in MS lesions, suggesting the technique could offer valuable insights. This milestone supports the development of Quantum BioPharma's MS drug candidate, Lucid-MS, which targets neurodegenerative and metabolic disorders.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The company's newsroom provides the latest updates at https://nnw.fm/QNTM. The study's progress represents a step forward in understanding MS pathology and potentially improving patient outcomes.
